Doximity (NYSE:DOCS - Get Free Report) had its price target boosted by investment analysts at Canaccord Genuity Group from $36.00 to $40.00 in a research report issued on Friday, Benzinga reports. The firm presently has a "buy" rating on the stock. Canaccord Genuity Group's price objective indicates a potential upside of 24.36% from the stock's previous close.
Several other equities analysts have also commented on the company. Evercore set a $35.00 target price on Doximity in a research note on Tuesday, September 29th. Piper Sandler reissued an "overweight" rating and issued a $47.00 price target (up from $42.00) on shares of Doximity in a research note on Friday, August 7th. Wells Fargo & Company cut Doximity from an "equal weight" rating to an "underweight" rating and set a $18.00 price target for the company. in a report on Monday, August 10th. Barclays lifted their price target on Doximity from $20.00 to $27.00 and gave the company an "equal weight" rating in a report on Friday, August 21st. Finally, Truist Financial increased their price objective on shares of Doximity from $19.00 to $24.00 and gave the stock a "hold" rating in a report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Doximity presently has a consensus rating of "Hold" and a consensus price target of $30.45.
Read Our Latest Report on DOCS
Doximity Price Performance
DOCS traded down $1.02 during trading on Friday, hitting $32.16. The company's stock had a trading volume of 2,769,843 shares, compared to its average volume of 3,882,713. The firm's 50 day moving average price is $28.95 and its 200-day moving average price is $25.55. The stock has a market cap of $5.73 billion, a PE ratio of 37.98, a PEG ratio of 27.12 and a beta of 1.29. Doximity has a twelve month low of $17.15 and a twelve month high of $58.24.
Doximity (NYSE:DOCS - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.13. The company had revenue of $156.62 million for the quarter. Doximity had a return on equity of 18.06% and a net margin of 25.48%. The company's revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.36 EPS. Equities analysts anticipate that Doximity will post 0.74 earnings per share for the current year.
Insider Buying and Selling
In other Doximity news, Director Watkin Phoebe L. Yang sold 1,290 shares of the business's stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $26.71, for a total transaction of $34,455.90. Following the completion of the sale, the director owned 24,744 shares of the company's stock, valued at approximately $660,912.24. The trade was a 4.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kira Wampler sold 2,000 shares of the company's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $32.89, for a total value of $65,780.00. Following the sale, the director owned 27,923 shares of the company's stock, valued at $918,387.47. This represents a 6.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 13,750 shares of company stock valued at $386,310. 31.80% of the stock is currently owned by company insiders.
Institutional Trading of Doximity
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Signaturefd LLC increased its stake in Doximity by 10.4% during the 3rd quarter. Signaturefd LLC now owns 4,205 shares of the company's stock worth $119,000 after buying an additional 397 shares during the period. Allworth Financial LP lifted its holdings in Doximity by 29.3% in the 3rd quarter. Allworth Financial LP now owns 2,642 shares of the company's stock worth $75,000 after buying an additional 599 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Doximity by 59.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the company's stock valued at $53,000 after buying an additional 695 shares during the last quarter. Apella Capital LLC boosted its position in Doximity by 1.4% in the 3rd quarter. Apella Capital LLC now owns 59,488 shares of the company's stock valued at $1,647,000 after buying an additional 802 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in Doximity by 19.8% in the 3rd quarter. GAMMA Investing LLC now owns 5,834 shares of the company's stock valued at $165,000 after buying an additional 963 shares during the last quarter. Institutional investors and hedge funds own 87.19% of the company's stock.
Key Doximity News
Here are the key news stories impacting Doximity this week:
- Positive Sentiment: Doximity reported fiscal Q2 2027 revenue of $174.5 million and earnings of $0.36 per share, beating estimates. It also forecast Q3 revenue of $195–$196 million and fiscal 2027 revenue of $678–$683 million, both above consensus. Management cited record engagement, a 51% adjusted EBITDA margin, and more than 190 health systems purchasing its AI suite. Fiscal 2027 Q2 results
- Positive Sentiment: Needham reaffirmed its Buy rating and $41 price target, signaling potential upside from the current share price. Needham analyst rating
- Negative Sentiment: The stock’s weak response contrasts with the earnings beat. Quarterly revenue grew 3.6% year over year, while EPS declined from $0.45 a year earlier to $0.36—potentially raising concerns about the pace of growth and earnings trends. Doximity quarterly results and stock reaction
- Negative Sentiment: Several law firms highlighted a securities class action and the November 16 lead-plaintiff deadline. The complaint alleges that Doximity misrepresented the contribution of its Newsfeed advertising product to growth; these claims have not been proven, but the litigation may add investor uncertainty. Class action deadline notice
- Neutral Sentiment: A director sold 2,000 shares under a pre-arranged Rule 10b5-1 plan. The transaction was relatively small and scheduled in advance, so it may have limited significance on its own. Director share sale
About Doximity
(
Get Free Report)
Doximity, Inc operates a digital platform designed for medical professionals in the United States. Its network connects physicians, nurse practitioners, physician assistants, pharmacists and other healthcare professionals, providing tools for professional communication, collaboration and career development.
The company offers services including secure messaging, telehealth, digital faxing, physician scheduling and professional networking. Doximity also provides medical news and educational content, as well as recruiting and job-search resources for healthcare professionals.
Doximity generates additional revenue through digital marketing and engagement solutions for pharmaceutical companies, healthcare organizations and health systems.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
